A Phase 3 clinical trial of semaglutide changed status as of August 7, 2026. The study, titled "A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight," is registered under trial ID NCT05726227.
The trial's current status is listed as active, not recruiting. This means the study is ongoing but is not currently enrolling new participants.
Semaglutide is an approved compound, and this trial is examining its use specifically in children and teenagers with excess body weight. The study is in Phase 3, a late stage of clinical testing typically conducted before or alongside regulatory review.
No results have been reported for this trial update. This brief reflects only the status and phase information available as of the listed date. Readers should not infer efficacy or safety outcomes from a status change alone.
Those interested in tracking this trial further can consult the official registration for updates on enrollment, completion, or results as they become available. For broader context on semaglutide, readers can consult the compound overview.